Conveners
RADIOTHERAPY SESSION
- Giacomo Cuttone (LNS)
- Roberto Orecchia (european institute of oncology)
RADIOTHERAPY SESSION
- Giacomo Cuttone (LNS)
- Roberto Orecchia (european institute of oncology)
-
Prof. Roberto Orecchia (european institute of oncology)04/09/2014, 08:30Cancer remains leading cause of death globally. Epidemiology studies estimated that 7.6 million deaths worldwide were due to cancer with 12.7 million new cases per year being reported worldwide. A significant proportion of this burden is borne by developing countries; 63% of cancer deaths are reported to be from developing countries. If uncontrolled cell growth or metastatic spread occurs it...Go to contribution page
-
Giacomo Cuttone (LNS)04/09/2014, 09:00The clinical development of radiation oncology has been historically connected to particle accelerator development and availability. In hadrontherapy this statement is even more true even considering complexity and cost investment. In this contribution will be presented the history of particle accelerator for hadrontherapy together with their actual status . In order to have a wider ...Go to contribution page
-
Luigi Picardi (ENEA Frascati)04/09/2014, 09:30The TOP IMPLART project is a program aiming the construction of a prototype facility for protontherapy application carried on in ENEA (Italian National agency for new technologies, Energy and sustainable economic development) in collaboration with con ISS (Italian National Institute of Health) and IFO-IRE (Regina Elena National Cancer Institute in Rome) and with a Regione Lazio grant. The...Go to contribution page
-
George El Fakhri (University of Harward)04/09/2014, 10:30
-
Prof. Guido Baroni (Politecnico di Milano - Fondazione CNAO)04/09/2014, 11:00A key challenge in radiation oncology is accurate delivery of the prescribed dose to tumours that move due to respiratory activity. Tumour tracking involves real-time target localisation and correction of radiation beam geometry to compensate for motion. Intra-fractional uncertainties in tumour localisation are crucial issue in particle therapy (proton therapy, carbon-ion therapy), because...Go to contribution page
-
Vincenzo Patera (ROMA1;LNF)04/09/2014, 11:30The use of proton and carbon beams to cure deep solid tumors (particle therapy) has became a widespread clinical practice. The favorable dose deposition pattern and the enhanced radiobiological effectiveness of light ion beams are valid tools to increase the local control probability and to spare the surrounding healthy tissues. The superior ballistic precision in dose release of these...Go to contribution page